Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target at $5.17

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $5.17.

A number of research firms have issued reports on SGMO. Wells Fargo & Company cut their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating for the company in a research note on Tuesday, December 31st. StockNews.com lowered shares of Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, December 24th. Truist Financial decreased their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Finally, Jefferies Financial Group decreased their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating on the stock in a report on Tuesday, December 31st.

Institutional Trading of Sangamo Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. SBI Securities Co. Ltd. bought a new position in Sangamo Therapeutics in the 4th quarter worth $28,000. XTX Topco Ltd boosted its stake in shares of Sangamo Therapeutics by 167.8% in the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 64,981 shares during the period. Geode Capital Management LLC grew its position in shares of Sangamo Therapeutics by 14.6% during the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company's stock worth $1,853,000 after purchasing an additional 272,123 shares in the last quarter. State Street Corp grew its position in shares of Sangamo Therapeutics by 28.0% during the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company's stock worth $576,000 after purchasing an additional 145,400 shares in the last quarter. Finally, Golden State Equity Partners lifted its holdings in Sangamo Therapeutics by 2,592.3% in the 4th quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company's stock worth $332,000 after purchasing an additional 313,587 shares in the last quarter. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Trading Down 1.6 %

SGMO stock traded down $0.01 on Thursday, hitting $0.74. The company had a trading volume of 6,353,031 shares, compared to its average volume of 8,405,018. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The stock has a market cap of $165.88 million, a price-to-earnings ratio of -0.98 and a beta of 1.57. The stock's 50-day simple moving average is $0.90 and its 200 day simple moving average is $1.39.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). The firm had revenue of $7.55 million during the quarter, compared to analysts' expectations of $11.70 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. Research analysts forecast that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.